Computational and in vitro targeting of HUVECs by ARA-Linker-TGFαL3 through VEGFR2

References

• Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(2):34.
   PubMed Web of Science ®Google Scholar
• Teleanu RI, Chircov C, Grumezescu AM, et al. Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med. 2019;9:84. doi:10.3390/jcm9010084
   PubMed Web of Science ®Google Scholar
• Shah AA, Kamal MA, Akhtar S. Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. Curr Drug Metab. 2021 //;22:50–59.
   PubMed Web of Science ®Google Scholar
• Ceci C, Atzori MG, Lacal PM, et al. Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models. Int J Mol Sci. 2020;21:1388. doi:10.3390/ijms21041388
   PubMed Web of Science ®Google Scholar
• Thieltges KM, Avramovic D, Piscitelli CL, et al. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling. Angiogenesis. 2018 2018/08/01;21:533–543. doi:10.1007/s10456-018-9606-9
   PubMed Web of Science ®Google Scholar
• Wang X, Bove AM, Simone G, et al. Molecular bases of VEGFR-2-Mediated physiological function and pathological role [Review]. Front Cell Dev Biol. 2020;8.
   Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell. 2002;110(6):763–773. doi:10.1016/S0092-8674(02)00940-6
   PubMed Web of Science ®Google Scholar
• Bueter W, Dammann O, Zscheppang K, et al. Erbb receptors in fetal endothelium–a potential linkage point for inflammation-associated neonatal disorders. Cytokine. 2006 Dec;36:267–275. doi:10.1016/j.cyto.2007.02.002
   PubMed Web of Science ®Google Scholar
• Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res. 2005;11:4521–4532. doi:10.1158/1078-0432.CCR-04-1954
   PubMed Web of Science ®Google Scholar
• Dokala A, Thakur S. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene. 2017;36(17):2337–2344. doi:10.1038/onc.2016.393
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15–31. doi:10.1517/14728222.2011.648617
   PubMed Web of Science ®Google Scholar
• Lim D, Kim KS, Kim H, et al. Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium. Oncotarget. 2017;8:37550–37560. doi:10.18632/oncotarget.17197
   PubMedGoogle Scholar
• Hsuan JJ. Transforming Growth Factor (TGF) alpha. In: Martini L, editor. Encyclopedia of endocrine diseases. New York: The University of California: Elsevier; 2004. p. 605–611.
   Google Scholar
• Nestor JJ, Newman SR, DeLustro B, et al. A synthetic fragment of rat transforming growth factor α with receptor binding and antigenic properties. Biochem Biophys Res Commun. 1985;129:226–232. doi:10.1016/0006-291X(85)91426-3
   PubMed Web of Science ®Google Scholar
• Amjadi G, Parivar K, Mousavi SF, et al. Anti-cancer effects of recombinant arazyme from Serratia Proteomaculans. JBUON. 2020;25:531–542.
   Google Scholar
• Ghadaksaz A, Imani Fooladi AA, Mahmoodzadeh Hosseini H, et al. ARA-linker-TGFαL3: a novel chimera protein to target breast cancer cells. Med Oncol. 2021 2021/07/17;38:96. doi:10.1007/s12032-021-01546-2
   PubMed Web of Science ®Google Scholar
• Ghadaksaz A, Imani Fooladi AA, Mahmoodzadeh Hosseini H, et al. Targeting the EGFR in cancer cells by fusion protein consisting of arazyme and third loop of TGF-alpha: an in silico study. J Biomol Struct Dyn. 2022 2022/12/12;40(22):11744–11757. doi:10.1080/07391102.2021.1963318
   PubMed Web of Science ®Google Scholar
• Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein-protein docking. Nature Protocols. 2017 Feb;12:255–278. doi:10.1038/nprot.2016.169
   PubMed Web of Science ®Google Scholar
• Pierce BG, Wiehe K, Hwang H, et al. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics. 2014 Jun 15;30:1771–1773. doi:10.1093/bioinformatics/btu097
   PubMed Web of Science ®Google Scholar
• Schneidman-Duhovny D, Inbar Y, Nussinov R, et al. Patchdock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33(suppl_2):W363–W367. doi:10.1093/nar/gki481
   PubMed Web of Science ®Google Scholar
• Xue LC, Rodrigues JP, Kastritis PL, et al. PRODIGY: a web server for predicting the binding affinity of protein–protein complexes. Bioinformatics. 2016;32:3676–3678. doi:10.1093/bioinformatics/btw514
   PubMed Web of Science ®Google Scholar
• Romero-Molina S, Ruiz-Blanco YB, Mieres-Perez J, et al. PPI-Affinity: a web tool for the prediction and optimization of protein–peptide and protein–protein binding affinity. J Proteome Research. 2022 2022/08/05;21(8):1829–1841. doi:10.1021/acs.jproteome.2c00020
   PubMedGoogle Scholar
• Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys. 2007;126:014101–7. doi:10.1063/1.2408420
   PubMed Web of Science ®Google Scholar
• Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys. 1981;52:7182–7190. doi:10.1063/1.328693
   Web of Science ®Google Scholar
• Hess B, Bekker H, Berendsen HJC, et al. Lincs: a linear constraint solver for molecular simulations. J Comput Chem. 1997;18:1463–1472.
   Web of Science ®Google Scholar
• Tresanco MSV, Valdes-Tresanco ME, Valiente PA, et al. gmx_MMPBSA. Zenodo; May 2021.
   Google Scholar
• Miller BR, McGee TD, Swails JM, et al. Mmpbsa.py: an efficient program for end-state free energy calculations. J Chem Theory Comput. 2012 2012/09/11;8:3314–3321. doi:10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Chen F, Liu H, Sun H, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein–protein binding free energies and re-rank binding poses generated by protein–protein docking. Phys Chem Chem Phys. 2016;18:22129–22139. doi:10.1039/C6CP03670H
   PubMed Web of Science ®Google Scholar
• Massova I, Kollman PA. Computational alanine scanning to probe protein−Protein interactions: a novel approach To evaluate binding free energies. J Am Chem Soc. 1999 1999/09/01;121:8133–8143. doi:10.1021/ja990935j
   Web of Science ®Google Scholar
• Safari E, Zavaran Hosseini A, Hassan Z, et al. Cytotoxic effect of immunotoxin containing the truncated form of pseudomonas Exotoxin A and Anti-VEGFR2 on HUVEC and MCF-7 cell lines. Cell J. 2014 Summer;16:203–210.
   PubMed Web of Science ®Google Scholar
• Supino R. Mtt assays. In: O’Hare S, Atterwill CK, editor. In vitro toxicity testing protocols. Totowa, NJ: Humana Press; 1995. p. 137–149.
   Google Scholar
• Abdolmaleki Z, Arab HA, Amanpour S, et al. Anti-angiogenic effects of ethanolic extract of Artemisia sieberi compared to its active substance, artemisinin. Rev Bras Farmacogn. 2016;26:326–333. doi:10.1016/j.bjp.2015.11.008
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978. doi:10.3389/fimmu.2018.00978
   PubMed Web of Science ®Google Scholar
• Lee WS, Pyun B-J, Kim S-W, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. mAbs. 2015 2015/09/03;7(5):957–968. doi:10.1080/19420862.2015.1045168
   PubMed Web of Science ®Google Scholar
• Samoedra RS, Sari FN, Pratama SK. Virtual prediction of lycopene and quercetin effects on angiogenesis through VEGFR-2 pathway. JSMARTech: J Smart Bioprospecting Technol. 2020;2(1):007–013.
   Google Scholar
• Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920–1925. doi:10.1158/1078-0432.CCR-12-2911
   PubMed Web of Science ®Google Scholar
• Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opinion on Biol Ther. 2013 Aug;13(8):1187–1196. doi:10.1517/14712598.2013.810717
   PubMed Web of Science ®Google Scholar
• Willis CD, Poluzzi C, Mongiat M, et al. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells. The FEBS Journal. 2013 May;280(10):2271–2284. doi:10.1111/febs.12164
   PubMed Web of Science ®Google Scholar
• Guterres H, Im W. Improving protein-ligand docking results with high-throughput molecular dynamics simulations. J Chem Inf Model. 2020 2020/04/27;60:2189–2198. doi:10.1021/acs.jcim.0c00057
   PubMed Web of Science ®Google Scholar
• Roy S, Khan S, Jairajpuri DS, et al. Investigation of sphingosine kinase 1 inhibitory potential of cinchonine and colcemid targeting anticancer therapy. J Biomol Struct Dyn. 2021;40(14):1–13.
   Web of Science ®Google Scholar
• Brozzo MS, Bjelić S, Kisko K, et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood. 2012;119(7):1781–1788. doi:10.1182/blood-2011-11-390922
   PubMed Web of Science ®Google Scholar
• Lobanov MY, Bogatyreva N, Galzitskaya O. Radius of gyration as an indicator of protein structure compactness. Mol Biol. 2008;42:623–628. doi:10.1134/S0026893308040195
   Web of Science ®Google Scholar
• van Meerloo J, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay. In: Cree IA, editor. Cancer cell culture: methods and protocols. Totowa, NJ: Humana Press; 2011. p. 237–245.
   Google Scholar
• Naderi S, Roshan R, Behdani M, et al. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin. Immunopharmacol Immunotoxicol. 2021 2021/03/04;43:230–238. doi:10.1080/08923973.2021.1888114
   PubMed Web of Science ®Google Scholar
• Langari J, Karimipoor M, Golkar M, et al. In vitro evaluation of Vegf-Pseudomonas Exotoxin: A conjugated on tumor cells. Adv Biomed Res. 2017;6:144–144. doi:10.4103/2277-9175.218691
   PubMedGoogle Scholar
• Chen W-w, Zhang H-r, Huang Z-G, et al. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity. Protein Expr Purif. 2021 2021/09/01/;185:105893. doi:10.1016/j.pep.2021.105893
   PubMed Web of Science ®Google Scholar
• Acheampong DO, Tang M, Wang Y, et al. A novel fusion antibody exhibits antiangiogenic activity and stimulates NK cell-mediated immune surveillance through fused NKG2D ligand. J Immunother. 2017;40:94–103. doi:10.1097/CJI.0000000000000157
   PubMed Web of Science ®Google Scholar
• Kim IS, Yang EJ, Shin DH, et al. Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells. Mol Med Rep. 2014;10:1025–1029. doi:10.3892/mmr.2014.2231
   PubMed Web of Science ®Google Scholar
• Zhao XC, Dou GR, Wang L, et al. Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells. Neoplasia (New York, NY). 2013 Jul;15:815–825.
   PubMed Web of Science ®Google Scholar
• Danilucci TM, Santos PK, Pachane BC, et al. Recombinant RGD-disintegrin DisBa-01 blocks integrin αvβ3 and impairs VEGF signaling in endothelial cells. Cell Commun Signal. 2019 2019/03/20;17:27. doi:10.1186/s12964-019-0339-1
   PubMed Web of Science ®Google Scholar
• Liu X, Wang W, Samarsky D, et al. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res. 2014 Oct;42:11805–11817. doi:10.1093/nar/gku831
   PubMed Web of Science ®Google Scholar